Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07232758

Safety, Tolerability and Pharmacokinetic Studies of HRS-2183 for Injection in Healthy Chinese Subjects After Single and Multiple Administration

This study mainly evaluated the safety and tolerability, as well as the pharmacokinetic characteristics, of the injectable drug HRS-2183 after single and multiple administrations in healthy subjects.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Qilu Hospital of Shandong University

Jinan, Shandong, 250100, China

Location status: Recruiting

Location contact

Wei Zhao

PRINCIPAL_INVESTIGATOR

Yuguo Chen

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male and female subjects, aged 18 to 45 years.
  • Body weight and Body Mass Index (BMI) within a specified range (e.g., BMI 19.0-26.0 kg/m²).
  • Agreement to use highly effective contraception during the study period and for a specified duration after the last dose. No plans for pregnancy, sperm/egg donation.
  • Voluntarily provides written informed consent to participate in the study.

Exclusion criteria

  • History of significant allergies to any food or drug, especially to the investigational product, its components, or drugs of a similar class.
  • History or current presence of any clinically significant disease in major organ systems (e.g., cardiovascular, hepatic, renal, neurological, etc.).
  • Any clinically significant abnormalities found during screening assessments (including physical examination, vital signs, and laboratory tests).
  • Clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening.
  • Evidence of impaired renal function based on laboratory tests (e.g., eGFR, serum creatinine).
  • Positive screening for specified infectious diseases (e.g., HIV, HBV, HCV, Syphilis).
  • Use of any medication (including prescription, OTC, and herbal) within a specified period before the study.
  • Excessive consumption of certain beverages (e.g., caffeine, grapefruit juice) or inability to adhere to dietary restrictions.
  • History of major surgery within the past 3 months or planned surgery during the study period.
  • Participation in another clinical trial within the past 3 months.
  • Significant blood loss, blood donation, or transfusion within the past 3 months.
  • History of excessive alcohol consumption or unwillingness to abstain during the study.
  • History of heavy smoking or unwillingness to abstain during the study.
  • History of drug abuse or positive drug screening test.
  • Inability to tolerate venous access or history of fainting during blood draws.
  • Inability to comply with the standardized diet provided during the study.
  • Any other reason that, in the opinion of the investigator, makes the subject unsuitable for the study.

Treatment and study plan

HRS-2183

Drug

HRS-2183

Placebo

Drug

placebo

Primary outcomes

  1. Incidence and severity of any adverse events

    Time frame: Evaluation was performed up to the seventh day / the 16th day

Secondary outcomes

  1. Tmax (Pharmacokinetic Parameters after a Single Dose)

    Time frame: Evaluation was performed up to the third day

  2. Cmax(Pharmacokinetic Parameters after a Single Dose)

    Time frame: Evaluation was performed up to the third day

  3. AUC0-t(Pharmacokinetic Parameters after a Single Dose)

    Time frame: Evaluation was performed up to the third day

  4. AUC0-∞(Pharmacokinetic Parameters after a Single Dose)

    Time frame: Evaluation was performed up to the third day

  5. t1/2(Pharmacokinetic Parameters after a Single Dose)

    Time frame: Evaluation was performed up to the third day

  6. CLz(Pharmacokinetic Parameters after a Single Dose)

    Time frame: Evaluation was performed up to the third day

  7. Vz(Pharmacokinetic Parameters after a Single Dose)

    Time frame: Evaluation was performed up to the third day

  8. Ae0-t(Pharmacokinetic Parameters after a Single Dose)

    Time frame: Evaluation was performed up to the third day

  9. Fe0-t(Pharmacokinetic Parameters after a Single Dose)

    Time frame: Evaluation was performed up to the third day

  10. CLr(Pharmacokinetic Parameters after a Single Dose)

    Time frame: Evaluation was performed up to the third day

  11. Tmax(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  12. Cmin,ss(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  13. Cmax,ss(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  14. Cav(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  15. AUC0-t,ss(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  16. AUC0-τ,ss(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  17. AUC0-∞,ss(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  18. t1/2(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  19. CLss(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  20. Vss(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  21. Rac(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

  22. DF(Pharmacokinetic Parameters after Multiple Doses)

    Time frame: Evaluation was performed up to the 12th day

Study contacts

Contact information is provided by the study sponsor or research team.

Yuanyuan Huang

CONTACT

[email protected]

+0518-82342973

Sponsors and collaborators

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd.

Industry

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 18, 2025
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.